SCHEMBL1779388

SCHEMBL1779388

CCOC(=O)C1=CCC(C)CC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
TSHR P16473 4/20 0.39
KDM4E B2RXH2 4/20 0.38
LMNA P02545 4/20 0.38
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 2/20 0.36
KMT2A Q03164 4/20 0.36
MAPT P10636 3/20 0.36
HSD17B10 Q99714 3/20 0.36
MEN1 O00255 3/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 2/20 0.36
ALOX15 P16050 2/20 0.35
CASP1 P29466 1/20 0.35
ALOX12 P18054 1/20 0.35
CA12 O43570 3/20 0.35
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA7 P43166 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL818456 0.84 CA12 (0.44) ALDH1A1TSHRKDM4ELMNAHTT
SCHEMBL5338308 0.76 KMT2A (0.42) ALDH1A1TSHRKDM4ELMNASMN1; SMN2
SCHEMBL1781929 0.75 CCR2 (0.37) ALDH1A1KMT2AMEN1
SCHEMBL28815411 0.73 TSHR (0.39) ALDH1A1TSHRKDM4ELMNASMN1; SMN2
SCHEMBL27991845 0.73 TSHR (0.39) ALDH1A1TSHRKDM4ELMNASMN1; SMN2
SCHEMBL21185794 0.73 POLB (0.43) ALDH1A1TSHRKDM4ELMNAHTT
SCHEMBL818117 0.71 ALDH1A1 (0.46) ALDH1A1TSHRKDM4ELMNASMN1; SMN2
SCHEMBL1781029 0.70 KDM4E (0.40) ALDH1A1TSHRKDM4ELMNAHTT
SCHEMBL5799259 0.70 GSTP1 (0.44) ALDH1A1TSHRKDM4ELMNASMN1; SMN2
SCHEMBL31196992 0.69 TSHR (0.48) ALDH1A1TSHRKDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507559-B2 Cyclohexenyl modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-13 US disclosed
EP-2318352-B1 CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2012-12-19 EP disclosed
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
EP-2318352-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-05-11 EP disclosed
WO-2010009068-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 ALDH1A1 917/4885TSHR 294/4885KDM4E 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.